The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.
Your search for psilocybin returned 17 results
Percentage of heavy drinking days reduced with psilocybin combined with psychotherapy versus active placebo plus psychotherapy
The FDA has granted Breakthrough Therapy designation to psilocybin for the treatment of major depressive disorder.
Results from a recent study published in The Lancet Psychiatry demonstrates preliminary support for the safety and efficacy of the hallucinogenic compound, psilocybin, for the management of treatment-resistant depression.
A single moderate-dose of psilocybin (a hallucinogenic compound contained in psychedelic mushrooms) was found to produce enduring anxiolytic and antidepressant effects in distressed cancer patients with life-threatening diagnoses.
According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.
A single dose of psilocybin can alleviate negative moods in patients with life-threatening cancer, a new study has found.
The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram
Colorado voters approved a measure to make the medical use of ‘magic mushrooms’ legal, paving the way for its use in treating several mental health disorders